Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model

The present study evaluates neuroprotection in a marmoset MPTP (1-methyl-1,2,3,6-tetrahydropyridine) model representing early Parkinson's disease (PD). The anti-glutamatergic compound riluzole is used as a model compound for neuroprotection. The compound is one of the few protective compounds u...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropharmacology 2012-03, Vol.62 (4), p.1700-1707
Hauptverfasser:	Verhave, Peternella S., Jongsma, Marjan J., Van Den Berg, Roland M., Vanwersch, Raymond A.P., Smit, August B., Philippens, Ingrid H.C.H.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Behavior Callithrix Corpus Striatum - drug effects Corpus Striatum - metabolism Dopamine Dopamine - metabolism Dopaminergic Neurons - drug effects Dopaminergic Neurons - metabolism Female Male Marmoset MPTP MPTP Poisoning - drug therapy Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Parkinson's disease Riluzole Riluzole - pharmacology Riluzole - therapeutic use Sleep Substantia Nigra - drug effects Substantia Nigra - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!